Please login to the form below

Not currently logged in
Email:
Password:

Bone cancer drug given priority review

Supported by data from 18 clinical trials, Amgen's denosumab has been given FDA priority review for bone cancer

The US Food and Drug Administration (FDA) has granted priority review to Amgen's denosumab to treat bone metastases in cancer patients. Bone metastases, most commonly associated with cancers of the prostate, lung and breast, can cause skeletal related events (SREs), such as fractures or spinal cord compression.

Denosumab, a subcutaneous RANK ligand inhibitor, is already approved for postmenopausal women with osteoporosis who are at high risk for fractures. Denosumab is the first compound to target the RANK/RANKL pathway, which is believed to play a crucial role in the bone destruction that cancer causes.

The development programme for denosumab is the largest Amgen has ever undertaken: over 11,000 patients have been enrolled in the trials in which the company is studying the compound in numerous tumour types across the spectrum of cancer-related bone diseases.

Dr Roger M Perlmutter, executive vice president of research and development at Amgen, said: "In clinical trials, denosumab has consistently demonstrated an ability to reduce the burden of complications from skeletal metastases, with a positive benefit-risk profile. We believe that this priority review designation underscores the potential for denosumab to provide a meaningful advance over the current standard of care for patients with metastatic bone disease."

Amgen included data from 18 studies involving almost 7,000 patients to support the submission. As well as the submission to the FDA in the US, Amgen has also submitted denosumab for approval in the EU, Australia, Canada and Switzerland, and plans to submit for approval in Japan. According to the FDA's priority review guidelines of six months, the Biologics License Application (BLA), which was submitted in mid-May, must now be processed before November 18, 2010.

19th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics